Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18052957 | 0.82 | ACACB (0.35) | CASP1CASP7HSD17B10 | |
| SCHEMBL17170040 | 0.82 | — | — | |
| SCHEMBL18681920 | 0.81 | — | — | |
| SCHEMBL22434887 | 0.78 | CASP1 (0.34) | CASP1CASP7HSD17B10 | |
| SCHEMBL18054226 | 0.76 | CYP19A1 (0.35) | CYP19A1ACLY | |
| SCHEMBL22434772 | 0.76 | HSD17B10 (0.41) | CYP19A1NQO2CASP1CASP7HSD17B10 | |
| SCHEMBL20977907 | 0.75 | KDR (0.32) | CYP19A1ACLY | |
| SCHEMBL22434888 | 0.74 | CASP1 (0.34) | CASP1CASP7HSD17B10 | |
| SCHEMBL22434780 | 0.74 | CYP19A1 (0.36) | CYP19A1NQO2 | |
| SCHEMBL20977899 | 0.73 | LMNA (0.34) | CYP19A1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261637-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3261638-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016137506-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | CYP19A1 2393/4885NQO2 2235/4885CASP1 3519/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | CYP19A1 2694/4885NQO2 2726/4885CASP1 3722/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | CYP19A1 2393/4885NQO2 2235/4885CASP1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.